Intrauterine Treatment of a Fetus with Familial Hypertrophic Cardiomyopathy Secondary to MYH7 Mutation by Meghan G. Hill et al.
CASE REPORT
Intrauterine Treatment of a Fetus with Familial Hypertrophic
Cardiomyopathy Secondary to MYH7 Mutation
Meghan G. Hill1 • Mehtab K. Sekhon1 • Kathryn L. Reed1 • Caroline F. Anderson1 •
Nydia D. Borjon1 • Jil C. Tardiff1 • Brent J. Barber1
Received: 6 May 2015 / Accepted: 4 August 2015 / Published online: 4 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract There is no clear consensus on optimal man-
agement of fetuses affected by familial hypertrophic car-
diomyopathy (HCM). Intrauterine treatment of the condition
has not been attempted in any standardized fashion. We
report the case of a fetus treated by maternal propranolol
during the third trimester after septal hypertrophy and dias-
tolic dysfunction was diagnosed on fetal echocardiogram.
The pregnancy went successfully to term, and fetal septal
hypertrophy was noted to improve prior to delivery.
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Case Report
Fetal hypertrophic cardiomyopathy (HCM) is most com-
monly seen in the setting of maternal diabetes mellitus [10,
11] and typically resolves spontaneously in the first few
weeks after delivery. Rarely, fetal HCM may be secondary
to a familial genetic mutation, classically a mutation in one
of the contractile proteins of the cardiac sarcomere. In this
situation, the condition can have serious long-term clinical
consequences [5].
We report the intrauterine course and management of a
baby girl born to a 30-year-old, G6P2 mother who initially
presented for prenatal care at 7 weeks of gestation. There
was no maternal history of diabetes mellitus, and gestational
diabetes screening performed in the pregnancy was normal.
Family History
The baby’s father and two older brothers carry a familial b-
myosin heavy chain mutation—MYH7 Lys657Gln
(K657Q)—resulting in HCM. The father was diagnosed
with HCM as a child and underwent heart transplantation at
age 33. The two brothers were diagnosed with HCM as
neonates following normal fetal echocardiograms without
evidence of fetal HCM. Their initial septal Z-scores at
1 day of age were ?3.7 (oldest) and ?3.0 (second brother).
They both were started on propranolol as neonates and
have been maintained on 3 mg/kg/day divided into three
daily doses since that time. In both boys, a decrease was
noted in the septal thickening with normalization of septal
Z-scores by 9 months.
In Utero/Fetal History
At 30 weeks of gestation, fetal HCM was suspected. At
that time, fetal echocardiogram revealed mild thickening of
the interventricular septum in diastole (4.7 mm; normal
2.5th–97.5th % = 1.8–3.6 mm) [3]. Repeated fetal echocar-
diography over the next several weeks revealed progressive
septal thickening with a maximal septal measurement at
35-weeks of gestation of 8.8 mm (Z-score ? 11.3; nor-
mal = 2.3–4.2 mm) [3] (Fig. 1). An abnormal ductus
venosus waveform was also noted at 35 weeks of gestation
with decreased late diastolic velocity during the a-wave of
15cm/sec (normal range at 35 weeks approximately
30-60cm/sec) [4]. (Fig. 2). We elected to initiate
intrauterine treatment based on two factors: (1) fetal dias-
tolic dysfunction and (2) the family history of improvement
in septal thickening (potentially associated with beta-
blocker treatment) noted in the two previous children with
HCM. Therefore, maternal administration of propranolol
& Meghan G. Hill
meghanhill@obgyn.arizona.edu
1 Department of Obstetrics and Gynecology, The University of
Arizona, College of Medicine, 1501 N. Campbell Ave, 8th
Floor, Tucson, AZ 85724, USA
123
Pediatr Cardiol (2015) 36:1774–1777
DOI 10.1007/s00246-015-1250-1
was initiated (10 mg orally three times daily). Over the
next several weeks, fetal echocardiograms were repeated
and revealed decreased septal thickness: 7.8 mm at
37 weeks of gestation and 7.6 mm at 38 weeks. The ductus
venosus waveform did not significantly change however
and remained abnormal.
Birth/Neonatal History
The baby girl was delivered via repeat cesarean section at
39 weeks and weighed 3470 g, length 49 cm, and had
Apgar scores of 9 and 9. The initial echocardiogram on the
first day of life noted a diastolic septal measurement of
7.9 mm (Z-score ?3.35). A small muscular VSD was also
noted. She did well, was initiated on propranolol and
discharged home on day three of life. She has been con-
tinued on propranolol (3 mg/kg/day in three divided daily
doses) and, like her brothers, has had regression of septal
hypertrophy and now has normal septal dimensions
(Table 1; Fig. 3). Genetic testing confirmed that she shares
the same b-myosin heavy chain mutation—MYH7
Lys657Gln (K657Q)—as her father and brothers.
Discussion
Hypertrophic cardiomyopathy is the most common famil-
ial heart disease occurring in approximately 1/500 young
adults [6]. Hypertrophic cardiomyopathy is inherited in an
autosomal dominant fashion and carries significant clinical





Fig. 2 Ductus venosus
waveform at 35-week estimated
gestational age
demonstrating an abnormal
waveform with a decreased
velocity in diastole. These
findings are consistent with fetal
diastolic dysfunction.
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consequences including a risk of sudden cardiac death. The
prevalence and clinical significance of fetal HCM is
unknown. In HCM, ventricular systolic function is typi-
cally hyperdynamic, but ventricular relaxation is impaired.
Increased ventricular diastolic filling pressure can decrease
umbilical vein and ductus venosus flow into the fetal heart
and is associated with elevated fetal central venous pres-
sure, which may result in effusions, ascites and fetal
demise [9]. Fetal diastolic dysfunction has been associated
with poor outcomes including fetal hydrops [5, 9]. We
observed a case of fetal familial HCM with diastolic dys-
function evidenced by an abnormal ductus venosus wave-
form. Secondary to the risk of hydrops and the previous
family history of a positive response to beta-blockers, we
elected to treat with maternal propranolol.
Beta-blocker treatment is recommended in the treatment
of children and adults with symptomatic HCM [2], but no
recommendations or previous reports of treatment of fetal
HCM have been published. Beta-blockers reduce heart
rate, decrease myocardial consumption and have a negative
inotropic effect. Beta-blockade has been shown to improve
echocardiographic parameters of LV diastolic function [1].
Treatment with beta-blockers in asymptomatic patients
with HCM is not established; however, we elected to treat
secondary to the observed abnormal parameters of fetal
diastolic function and the risk of fetal hydrops/demise.
While specific response to beta-blocker treatment is not
currently a documented feature of MYH7 HCM, beta-
blocker treatment in childhood HCM has been associated
with a reduction in cardiac hypertrophy and improved
survival [8]. It has been suggested that the rapid growth of
the heart in childhood may provide a favorable window of
opportunity for medical treatment in HCM [8]. This may
also apply to the rapidly growing fetal heart.
The use of beta-blockers is not without concern in
pregnancy. Beta-blockers are an FDA category C drug
because of reported risks of in utero exposure, resulting in
fetal growth restriction, heart defects, fetal and neonatal
bradycardia, neonatal hypoglycemia and neonatal respira-
tory depression. Fortunately, we did not observe any of
these fetal or neonatal complications.
While it is interesting to speculate on the encouraging
early results noted with beta-blocker treatment in this family
with an MYH7 mutation, it has been noted that HCM
genotype–phenotype prognostic correlations are difficult.
This is attributed to HCM being an ‘‘exceedingly complex
biologic entity with vast genetic heterogeneity’’ [7].
Clinical trials of fetal HCM treatmentwould be difficult to
accomplish, but we are encouraged by the results noted in
this case andwould recommend consideration of intrauterine
beta-blocker treatment for a fetus with suspected familial
HCM and evidence of diastolic dysfunction.
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Table 1 Change in intraventricular septal thickness in diastole (IVSd) with propranolol treatment for the index case. The IVSd Z-score was
calculated with the Detroit database at www.parameterz.com. Fetal Z-scores were calculated from 2.5th to 97.5th percentiles in [3]









































































Change in IVSd z-scores over time with propranolol treatment
Fig. 3 This figure shows the change in IVSd Z-scores of the index
case over time with propranolol treatment. The IVSd Z-score for the
index case at 35-week gestational age (GA) is also shown
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